| Literature DB >> 33609480 |
Peter Hermann1, Brian Appleby2, Jean-Philippe Brandel3, Byron Caughey4, Steven Collins5, Michael D Geschwind6, Alison Green7, Stephane Haïk3, Gabor G Kovacs8, Anna Ladogana9, Franc Llorens10, Simon Mead11, Noriyuki Nishida12, Suvankar Pal7, Piero Parchi13, Maurizio Pocchiari9, Katsuya Satoh14, Gianluigi Zanusso15, Inga Zerr16.
Abstract
Sporadic Creutzfeldt-Jakob disease is a fatal neurodegenerative disease caused by misfolded prion proteins (PrPSc). Effective therapeutics are currently not available and accurate diagnosis can be challenging. Clinical diagnostic criteria use a combination of characteristic neuropsychiatric symptoms, CSF proteins 14-3-3, MRI, and EEG. Supportive biomarkers, such as high CSF total tau, could aid the diagnostic process. However, discordant studies have led to controversies about the clinical value of some established surrogate biomarkers. Development and clinical application of disease-specific protein aggregation and amplification assays, such as real-time quaking induced conversion (RT-QuIC), have constituted major breakthroughs for the confident pre-mortem diagnosis of sporadic Creutzfeldt-Jakob disease. Updated criteria for the diagnosis of sporadic Creutzfeldt-Jakob disease, including application of RT-QuIC, should improve early clinical confirmation, surveillance, assessment of PrPSc seeding activity in different tissues, and trial monitoring. Moreover, emerging blood-based, prognostic, and potentially pre-symptomatic biomarker candidates are under investigation.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33609480 PMCID: PMC8285036 DOI: 10.1016/S1474-4422(20)30477-4
Source DB: PubMed Journal: Lancet Neurol ISSN: 1474-4422 Impact factor: 44.182